Open AccessReal-world single-center experience with entecavir and tenofovir disoproxil fumarate in treatment-naïve and experienced patients with chronic hepatitis B
Author(s) -
Young Min Kim,
Hyun Phil Shin,
Joung Il Lee,
Kwang Ro Joo,
Jae Myung,
Jung Won Jeon,
Jin Young Yoon,
Min Seob Kwak
Publication year - 2018
Publication title -
the saudi journal of gastroenterology/saudi journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.608
H-Index - 32
eISSN - 1998-4049
pISSN - 1319-3767
DOI - 10.4103/sjg.sjg_49_18
Subject(s) - medicine , entecavir , incidence (geometry) , cirrhosis , tenofovir , gastroenterology , hepatitis b , hepatitis b virus , medical record , chronic hepatitis , immunology , virus , lamivudine , human immunodeficiency virus (hiv) , physics , optics
The goal of antiviral therapy for chronic hepatitis B (CHB) is to improve survival of the patients by achieving a complete virological response (CVR). This study aimed to evaluate long-term efficacy of entecavir (ETV) and tenofovir disoproxil fumarate (TDF) in nucleos(t)ide analog (NA)-naïve and NA-experienced Korean patients with CHB and to determine the incidence of cirrhosis-related complications in these patients.